https://arolstar52-zhtest.hf.space/index.php?action=history&feed=atom&title=AB-PINACA
AB-PINACA - 版本历史
2026-07-18T06:47:14Z
在这个wiki上该页的修订历史
MediaWiki 1.43.9
https://arolstar52-zhtest.hf.space/index.php?title=AB-PINACA&diff=4159245&oldid=prev
imported>InternetArchiveBot：Add 1 book for verifiability (20251017sim)) #IABot (v2.0.9.5) (GreenC bot
2025-10-17T20:40:48Z
<p>Add 1 book for verifiability (20251017sim)) #IABot (v2.0.9.5) (<a href="/index.php?title=User:GreenC_bot&action=edit&redlink=1" class="new" title="User:GreenC bot（页面不存在）">GreenC bot</a></p>
<p><b>新页面</b></p><div>{{Drugbox<br />
| IUPAC_name = ''N''-[(1''S'')-1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-1''H''-indazole-3-carboxamide<br />
| image = AB-PINACA_structure-rev1.png<br />
<!--Clinical data--><br />
| tradename =<br />
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --><br />
| pregnancy_US = <!-- A / B / C / D / X --><br />
| pregnancy_category =<br />
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --><br />
| legal_CA = Schedule II<br />
| legal_UK = Class B<br />
| legal_US = Schedule I<!-- OTC / Rx-only / Schedule I, II, III, IV, V --><br />
| legal_DE = Anlage II<br />
| routes_of_administration =<br />
<br />
<!--Pharmacokinetic data--><br />
| bioavailability =<br />
| protein_bound =<br />
| metabolism =<br />
| elimination_half-life =<br />
| excretion =<br />
<br />
<!--Identifiers--><br />
| CAS_number_Ref = {{cascite|correct|CAS}}<br />
| CAS_number = 1445752-09-9<br />
| ATC_prefix =<br />
| ATC_suffix =<br />
| PubChem = 71301472<br />
| ChemSpiderID = 28537615<br />
| smiles = CCCCCn1c2ccccc2c(n1)C(=O)N[C@@H](C(C)C)C(=O)N<br />
| StdInChI = 1S/C18H26N4O2/c1-4-5-8-11-22-14-10-7-6-9-13(14)16(21-22)18(24)20-15(12(2)3)17(19)23/h6-7,9-10,12,15H,4-5,8,11H2,1-3H3,(H2,19,23)(H,20,24)/t15-/m0/s1<br />
| StdInChIKey = GIMHPAQOAAZSHS-HNNXBMFYSA-N<br />
| UNII_Ref = {{fdacite|correct|FDA}}<br />
| UNII = 6J3KC3S2PA<br />
<br />
<!--Chemical data--><br />
| C=18 | H=26 | N=4 | O=2<br />
}}<br />
<br />
'''AB-PINACA'''是一种[[有机化合物]]，化学式为[[C18H26N4O2|C<sub>18</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>]]。它最初由辉瑞公司于2009年作为镇痛药开发，<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/14038 | title=AB-PINACA | publisher=Cayman Chemical | access-date=25 June 2015 | archive-date=2015-06-26 | archive-url=https://web.archive.org/web/20150626123900/https://www.caymanchem.com/app/template/Product.vm/catalog/14038 | dead-url=no }}</ref><ref>{{cite journal | url=https://www.google.com/patents/WO2009106980A3 | title=Patent WO/2009/106980 - Indazole derivatives | access-date=2023-01-26 | archive-date=2016-05-27 | archive-url=https://web.archive.org/web/20160527082515/https://www.google.com/patents/WO2009106980A3 | dead-url=no }}</ref>并在2012年于日本首次被鉴定为{{le|合成大麻素|synthetic cannabinoids}}。<ref>{{Cite journal | vauthors = Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y | title = New cannabimimetic indazole derivatives, ''N''-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1''H''-indazole-3-carboxamide (AB-PINACA) and ''N''-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1''H''-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products | doi = 10.1007/s11419-012-0171-4 | journal = Forensic Toxicology | volume = 31 | pages = 93–100 | year = 2012 | s2cid = 25242453 }}</ref><br />
<br />
它是潜在的[[CB1受体|CB<sub>1</sub>受体]]（''K''<sub>i</sub>&nbsp;=&nbsp;2.87&nbsp;nM，[[EC50|EC<sub>50</sub>]]&nbsp;=&nbsp;1.2&nbsp;nM）和[[CB2受体|CB<sub>2</sub>受体]]（''K''<sub>i</sub>&nbsp;=&nbsp;0.88&nbsp;nM，EC<sub>50</sub>&nbsp;=&nbsp;2.5&nbsp;nM）的激动剂。<ref>{{cite journal | vauthors = Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M | display-authors = 6 | title = Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA | journal = ACS Chemical Neuroscience | volume = 6 | issue = 9 | pages = 1546–59 | date = September 2015 | pmid = 26134475 | doi = 10.1021/acschemneuro.5b00112 }}</ref><ref>{{cite journal | vauthors = Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF | display-authors = 6 | title = AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 354 | issue = 3 | pages = 328–39 | date = September 2015 | pmid = 26105953 | pmc = 4538877 | doi = 10.1124/jpet.115.225326 | url = http://jpet.aspetjournals.org/content/early/2015/06/23/jpet.115.225326.short | access-date = 2023-01-26 | archive-date = 2023-01-30 | archive-url = https://web.archive.org/web/20230130173202/https://jpet.aspetjournals.org/content/early/2015/06/23/jpet.115.225326.short | dead-url = no }}</ref><br />
<br />
这种合成大麻素有不少相关死亡和住院病例报告。<ref>{{cite journal | vauthors = Trecki J, Gerona RR, Schwartz MD | title = Synthetic Cannabinoid-Related Illnesses and Deaths | url = https://archive.org/details/sim_new-england-journal-of-medicine_the-new-england-journal-of-medicine_2015-07-09_373_2/page/102 | journal = The New England Journal of Medicine | volume = 373 | issue = 2 | pages = 103–7 | date = July 2015 | pmid = 26154784 | doi = 10.1056/NEJMp1505328 }}</ref><br />
<br />
== 参见 ==<br />
{{div col|colwidth=30em}}<br />
* [[5F-AB-PINACA]]<br />
* [[5F-ADB]]<br />
* [[5F-AMB]]<br />
* [[5F-APINACA]]<br />
* [[5F-CUMYL-PINACA]]<br />
* [[AB-CHFUPYCA]]<br />
* [[AB-FUBINACA]]<br />
* [[AB-PICA]]<br />
* [[ADB-CHMINACA]]<br />
* [[ADB-FUBINACA]]<br />
* [[ADB-PINACA]]<br />
* [[ADBICA]]<br />
* [[APICA (synthetic cannabinoid drug)|APICA]]<br />
* [[APINACA]]<br />
* [[MDMB-CHMICA]]<br />
* [[PX-3]]<br />
{{Div col end}}<br />
<br />
== 参考文献 ==<br />
{{reflist}}<br />
{{大麻素}}<br />
<br />
[[Category:大麻素]]<br />
[[Category:策划药]]<br />
[[Category:吲唑甲酰胺]]<br />
[[Category:正戊基化合物]]</div>
imported>InternetArchiveBot